Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples